Evidence map›Paper›PMID 33927346›Full record

ArticleBone marrow transplantation2021

Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation.

Kaito Harada, Shun-Ichi Kimura, Shigeo Fuji, Yuho Najima, Kimikazu Yakushijin, Naoyuki Uchida, Makoto Onizuka, Kazuhiro Ikegame, Shingo Yano, Naoki Shingai and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 15 institutions in 1 country.

Kaito HaradaDepartment of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan. k.harada@tsc.u-tokai.ac.jp.ORCID http://orcid.org/0000-0002-8462-7550
Shun-Ichi KimuraDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Shigeo FujiDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Yuho NajimaHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0001-8910-0021
Kimikazu YakushijinDepartment of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan.ORCID http://orcid.org/0000-0003-2511-7857
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0001-5952-5926
Makoto OnizukaDepartment of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.
Kazuhiro IkegameDepartment of Hematology, Hyogo College of Medicine Hospital, Nishinomiya, Japan.ORCID http://orcid.org/0000-0002-5421-7470
Shingo YanoClinical Oncology and Hematology, The Jikei University School of Medicine, Tokyo, Japan.
Naoki ShingaiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Ken-Ichi MatsuokaDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.ORCID http://orcid.org/0000-0001-7955-8266
Yasushi OnishiDepartment of Hematology, Tohoku University Hospital, Sendai, Japan.
Masashi SawaDepartment of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
Satoru TakadaLeukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan.
Toshiro KawakitaDepartment of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Takahiro FukudaHematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
Junya KandaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-6704-3633
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.ORCID http://orcid.org/0000-0003-4404-2870
Hideaki NakasoneDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.ORCID http://orcid.org/0000-0001-5812-9315
Jichi Medical University · JPTokai University · JPTokyo Metropolitan Komagome Hospital · JPAnjo Kosei Hospital · JPGunma Saiseikai Maebashi Hospital · JPHyogo Medical University · JPJikei University School of Medicine · JPKobe University Hospital · JPKumamoto Medical Center · JPKyoto University · JPOkayama University Hospital · JPOsaka International Cancer Institute · JPThe Japanese Data Center for Hematopoietic Cell Transplantation · JPTohoku University Hospital · JPToranomon Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although graft failure (GF) is a fatal complication after allogeneic stem cell transplantation (SCT), no mortality risk assessments after salvage SCT have been reported. We developed a comprehensive prognostic scoring system consisting of patient and comorbidity factors with 470 patients as a training cohort out of 940; these patients underwent salvage SCT for GF. The multivariate analysis demonstrated that older age, poorer performance status, a continuation of antimicrobial treatment, and severe organ dysfunction were independently associated with worse overall survival (OS) and non-relapse mortality (NRM). Based on each factor's hazard ratio, weighted scores of 1-3 were assigned to these factors. Using the summed scores (0-8), a prognostic scoring system successfully stratified outcomes after salvage SCT in the cohort. For patients in the low (0-2, n = 122), intermediate (3-4, n = 209), and high score (5-8, n = 110) groups, the 1-year OS was 62.8%, 40.8%, and 14.2%, respectively (P < 0.001), whereas the 1-year NRM was 24.1%, 43.9%, and 72.7%, respectively (P < 0.001). The prognostic value of the scoring system was confirmed in the validation cohort (n = 470). Our scoring system is useful for predicting survival after salvage SCT.

Indexed as

Hematopoietic Stem Cell TransplantationAgedHumansPrognosisRecurrenceRetrospective StudiesSalvage TherapyTransplantation, Homologous

Identifiers

PMID33927346
OpenAlexW3159076973

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.